Novo Licenses Orbis Oral Macrocycle Discovery
Orbis Medicines and Novo Nordisk entered a multi-target discovery and license collaboration for orally bioavailable synthetic macrocycles against undisclosed cardiometabolic targets. Orbis is eligible for up to $1.4 billion in upfront and development or…
